Loading...
XIDX
PYFA
Market cap341mUSD
Nov 12, Last price  
550.00IDR
Name

Pyridam Farma Tbk PT

Chart & Performance

D1W1MN
XIDX:PYFA chart
P/E
P/S
2.24
EPS
Div Yield, %
Shrs. gr., 5y
35.15%
Rev. gr., 5y
58.33%
Revenues
2.76t
+43.71%
61,336,546,45986,643,019,272119,580,973,204132,000,542,048140,858,442,443151,094,461,045176,730,979,672192,555,731,180222,302,407,528217,843,921,422216,951,583,953223,002,490,278250,445,853,364247,114,772,587277,398,061,739630,530,235,961715,425,027,099702,067,615,6051,920,811,833,0002,760,422,051,000
Net income
-379.67b
L+14.97%
1,729,406,2461,743,483,8692,308,877,3293,772,968,3594,199,202,9535,172,045,6805,308,221,3636,195,800,3382,661,022,0003,087,104,4655,146,317,0417,127,402,1688,447,447,9889,342,718,03922,104,364,2675,478,944,087275,241,310,307-85,220,974,920-330,246,642,000-379,670,100,000
CFO
-364.28b
L+158.28%
-2,729,962,9293,832,736,959736,542,4085,020,232,1519,538,086,2411,688,060,047-448,715,089-5,856,771,7771,472,541,37115,699,910,4342,827,335,8832,844,360,1871,757,637,35117,609,426,4091,112,220,08039,586,425,851275,241,310,307-103,982,859,768-141,041,645,000-364,284,727,000
Dividend
May 31, 20193.9995 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PT Pyridam Farma Tbk, an Indonesian-based enterprise, specializes in the development, production, and distribution of a broad spectrum of health-related products. Its offerings encompass pharmaceuticals, antibiotics, essential vitamins, dietary supplements, and traditional herbal remedies. The company's operations are divided into two main segments: Pharmaceutical Products and Contract Manufacturing Services, and Medical Device Products. Within its medical device division, the firm provides a variety of instruments and consumables. These include clinical waste management items, collection swabs and tubes, innerbox DCA, KF94 masks, parafilm, PCR extraction kits and their accompanying machinery, specimen bags, sterile containers, and tube stoppers. Furthermore, PT Pyridam Farma markets a diverse collection of skincare products, such as Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel. Its pharmaceutical portfolio addresses numerous therapeutic areas, including digestive and metabolic health, blood and blood-forming organ conditions, cardiovascular disorders, dermatological ailments, genitourinary system and sex hormone regulation, systemic corticosteroids, systemic antibacterial treatments, sensory organ issues, as well as musculoskeletal, nervous, and respiratory system conditions. Beyond medicinal lines, the company also develops and sells dietary supplements and preventive consumer health items, notably energy drinks and various healthy ready-to-consume beverages. A key area of its strategic focus involves conducting extensive research and development in biotechnology, life sciences, and medical science. Established in 1976, PT Pyridam Farma Tbk is headquartered in Jakarta, Indonesia.
IPO date
Oct 16, 2001
Employees
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT